TABLE 4

Current clinical trials on immunotherapy and chemoradiotherapy in mostly stage II and III nonsmall stage lung cancer (NSCLC)

ClinicalTrials.gov ID	Phase	NSCLC stage	IO-drug	Protocol	Primary end-point
Concurrent (+consolidation) regimen
NCT04202809	II	IIIA–B	Durvalumab	Chemotherapy induction→chemoradiotherapy ± durvalumab→surgery if resectable	PFS
NCT03694236	I/II	II/IIIA	Durvalumab	Chemoradiotherapy+durvalumab→surgery	pCR
NCT02343952	II	IIIA–B	Pembrolizumab	Chemoradiotherapy→pembrolizumab consolidation	PFS
NCT02987998	I	III	Pembrolizumab	Chemoradiotherapy+pembrolizumab	Safety
NCT03519971^#	III	Unresectable	Durvalumab	Chemoradiotherapy ± durvalumab	PFS
NCT04013542	I	II–III	Nivolumab/ ipilimumab	Radiotherapy+nivolumab/ipilimumab	Safety
NCT03523702	II	II–III	Pembrolizumab	Arm 1 (PD-L1 >50%): radiotherapy+pembrolizumab Arm 2 (PD-L1 1–49%): chemoradiotherapy	PFS
NCT03631784	II	III unresectable	Pembrolizumab	Chemoradiotherapy+pembrolizumab→ pembrolizumab consolidation	Safety, ORR
NCT03644823	II	III–IV	Atezolizumab	Radiotherapy+atezolizumab	Safety
Combination regimen
NCT04085250	II	III	Nivolumab	Chemotherapy ± nivolumab induction→ chemoradiotherapy→nivolumab consolidation or observation	PFS
NCT03589547	II	III	Durvalumab	Durvalumab→chemoradiotherapy→durvalumab	Safety, PFS
NCT04380636^#	III	III	Pembrolizumab	Arm 1: chemoradiotherapy+pembrolizumab→ pembrolizumab+placebo Arm 2: chemoradiotherapy+pembrolizumab→ pembrolizumab+olaparib Arm 3: chemoradiotherapy→durvalumab	PFS, OS
NCT03871153	II	Resectable III	Durvalumab	Chemoradiotherapy+durvalumab induction→surgery→durvalumab consolidation	pCR
NCT03693300	II	III	Durvalumab	Chemoradiotherapy→durvalumab (fixed dose)	Safety
NCT03285321	II	IIIA–B	Nivolumab/ ipilimumab	Chemoradiotherapy→nivolumab ± ipilimumab consolidation	PFS
NCT04026412^#	III	IIIA–C	Nivolumab/ ipilimumab	Arm 1: chemoradiotherapy+nivolumab→ nivolumab/ipilimumab consolidation Arm 2: chemoradiotherapy+nivolumab→ nivolumab consolidation Arm 3: chemoradiotherapy→durvalumab consolidation	PFS, OS
NCT04062708	II	III resectable	Durvalumab	Chemotherapy+durvalumab induction→ surgery→radiotherapy→durvalumab consolidation	pCR
NCT03237377	II	III resectable	Durvalumab/ tremelimumab	Radiotherapy+durvalumab ± tremelimumab→surgery	pCR
NCT03871153	II	III resectable	Durvalumab	Chemotherapy+durvalumab induction→radiotherapy+durvalumab→surgery→durvalumab consolidation	pCR
NCT03663166	I/II	III	Nivolumab/ ipilimumab	Chemoradiotherapy+ipilimumab→nivolumab consolidation	Safety, PFS
Induction regimen
NCT04287894	Ib	III	Durvalumab/ tremelimumab	Durvalumab+tremelimumab induction→chemoradiotherapy	Safety
NCT03102242	II	IIIA–B	Atezolizumab	Atezolizumab induction→chemoradiotherapy	DCR

Data obtained from www.clinicaltrials.gov on 7 August 2020. IO: immune-oncology; pCR: pathological complete response; PFS: progression-free survival; OS: overall survival: PD-L1: programmed death ligand 1; ORR: overall response rate; DCR: disease control rate. ^#: phase III trials.